<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87208">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01720251</url>
  </required_header>
  <id_info>
    <org_study_id>AN004T</org_study_id>
    <secondary_id>2011-002259-32</secondary_id>
    <nct_id>NCT01720251</nct_id>
  </id_info>
  <brief_title>Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy</brief_title>
  <official_title>Phase IIb Study to Assess the Efficacy, Safety and Tolerability of Two Dosing Regimens of AllerT in Comparison to Placebo in Adult Subjects Allergic to Birch Pollen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anergis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anergis</source>
  <oversight_info>
    <authority>Denmark: Danish Health and Medicines Authority</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Lithuania: State Medicine Control Agency - Ministry of Health</authority>
    <authority>Latvia: State Agency of Medicines</authority>
    <authority>Poland: Ministry of Health</authority>
    <authority>Sweden: Medical Products Agency</authority>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the trial is to demonstrate the efficacy of a two months pre-seasonal
      treatment with AllerT 100 µg maintenance dose in reducing symptoms of allergic
      rhinoconjunctivitis during the following birch pollen season
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Combined Rhinoconjunctivitis Symptom and Medication Score</measure>
    <time_frame>up to 6 weeks during the birch pollen season 2013</time_frame>
    <safety_issue>No</safety_issue>
    <description>The efficacy analysis will be performed on the symptom and medication data collected from the first day of the birch pollen season as defined by pollen counts in the air in each site region (from March to May 2013 depending on site region), to 42 days later or to the end of the pollen season, whichever comes first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>up to 6 weeks during the birch pollen season 2013</time_frame>
    <safety_issue>No</safety_issue>
    <description>mini-RQLQ questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability</measure>
    <time_frame>from start of treatment to 28 days after completion of treatment, i.e. for approximately 12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adverse events will be collected throughout the trial period and will be reported as Treatment emergent adverse events occurring between start of treatment and 28 days after completion of treatment for each subject</description>
  </secondary_outcome>
  <other_outcome>
    <measure>immunological markers: specific IgE and IgG4</measure>
    <time_frame>before treatment, 4 weeks after the last injection and 2 weeks before, at the peak time and within 2 weeks after the end of the expected birch pollen season 2013</time_frame>
    <safety_issue>No</safety_issue>
    <description>blood samples will be drawn at the above time points to measure immunological markers: specific IgE and IgG4</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Allergic Rhinitis</condition>
  <condition>Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC injections of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AllerT low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injections of AllerT 25 or 50 micrograms</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AllerT full dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SC injections of AllerT 50-100 micrograms</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>SC injections of placebo on days 1, 7, 14, 28 and 56</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AllerT low dose</intervention_name>
    <description>SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56</description>
    <arm_group_label>AllerT low dose</arm_group_label>
    <other_name>AllerT 25-50 micrograms</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AllerT full dose</intervention_name>
    <description>SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56</description>
    <arm_group_label>AllerT full dose</arm_group_label>
    <other_name>AllerT 50-100 micrograms</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate to severe allergic rhinoconjunctivitis to birch pollen:

               1. Score of symptoms of the Rhinoconjunctivitis Symptom Score (RSS) ≥ 12 during the
                  two preceding birch pollen seasons

               2. Previous use of anti-allergy medications during the two preceding birch pollen
                  seasons

               3. Positive SPT to birch pollen extract

               4. Positive specific IgE CAP test for Bet v 1

        Exclusion Criteria:

          -  uncontrolled asthma, FEV1 &lt; 80% of predicted

          -  previous SIT (specific immunotherapy) to birch pollen or any other SIT within 5 years

          -  clinical symptoms due to allergens other than birch pollen during the whole trial
             period

          -  history of anaphylaxis

          -  positive skin prick test to AllerT

          -  any other treatment or conditions which may increase the risk of the study for the
             subject or affect the efficacy assessments during the birch pollen season
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois Spertini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier universitaire vaudois, Lausanne, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allergiklinikken</name>
      <address>
        <city>Hellerup</city>
        <state>Copenhagen</state>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungemedicinsk Forskningsafdeling</name>
      <address>
        <city>Arhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinisk Institute</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Reims</name>
      <address>
        <city>Reims</city>
        <zip>51092</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Viktorija Vevere private practice of Allergology</name>
      <address>
        <city>Rezekne</city>
        <zip>4601</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paul Stradins Clinical University Hospital - Pulmonology Allergology</name>
      <address>
        <city>Riga</city>
        <zip>1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center of examination and treatment of allergic diseases</name>
      <address>
        <city>Riga</city>
        <zip>1003</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaunas Clinics University Hospital</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital</name>
      <address>
        <city>Vilnius</city>
        <zip>08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allergy Clinic JSC Perspektyvos</name>
      <address>
        <city>Vilnius</city>
        <zip>08431</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Antakalnio affiliation of the Vilnius City Allergy Center</name>
      <address>
        <city>Vilnius</city>
        <zip>10200</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alergologii Centrum</name>
      <address>
        <city>Lodz</city>
        <zip>90553</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPZOZ Uniwersytecki Szpital Kliniczny - Allergology</name>
      <address>
        <city>Lodz</city>
        <zip>90153</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alergotest</name>
      <address>
        <city>Lublin</city>
        <zip>20095</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alergo-Med</name>
      <address>
        <city>Tarnow</city>
        <zip>33100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Alergologii IRMED</name>
      <address>
        <city>Warszawa</city>
        <zip>01157</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silesian Piasts University of Medicine in Wrocław</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-368</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aler-med</name>
      <address>
        <city>Wroclaw</city>
        <zip>54203</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Przychodnia Lekarska Hipokrates</name>
      <address>
        <city>Zabrze</city>
        <zip>41800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital Skane</name>
      <address>
        <city>Lund</city>
        <zip>22185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orebro University Hospital</name>
      <address>
        <city>Orebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungavdelningen, Vastmanlands</name>
      <address>
        <city>Vasteras</city>
        <zip>72189</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <state>VD</state>
        <zip>1005</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>France</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 2, 2014</lastchanged_date>
  <firstreceived_date>October 29, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>allergic rhinitis</keyword>
  <keyword>birch pollen</keyword>
  <keyword>immunotherapy</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Conjunctivitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
